On October 28, 2025, Cocrystal Pharma, Inc. entered into a Securities Purchase Agreement to sell 739,426 units at $1.39 each, generating $1.03 million from four accredited investors, including insiders. Each unit includes one share of common stock and two warrants at $1.24 per share over 27 months.